Cite

HARVARD Citation

    Schneider, B. et al. (2019). Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer. CPT: pharmacometrics & systems pharmacology. pp. 577-586. [Online]. 
  
Back to record